دورية أكاديمية
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
| العنوان: | Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis |
|---|---|
| المؤلفون: | Nazarzadeh, M, Bidel, Z, Canoy, D, Copland, E, Bennett, DA, Dehghan, A, Davey Smith, G, Holman, RR, Woodward, M, Gupta, A, Adler, AI, Wamil, M, Sattar, N, Cushman, WC, McManus, RJ, Teo, K, Davis, BR, Chalmers, J, Pepine, CJ, Rahimi, K, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, N, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, B, Cutler, J, Devereaux, RB, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, J, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, C, Patel, A, Pfeffer, M, Poulter, NR, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, WH, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, ZY, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Pitt, B, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J |
| المصدر: | urn:ISSN:2213-8587 ; urn:ISSN:2213-8595 ; The Lancet Diabetes and Endocrinology, 10, 9, 645-654 |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2022 |
| المجموعة: | UNSW Sydney (The University of New South Wales): UNSWorks |
| مصطلحات موضوعية: | Heart Disease, Cardiovascular, Diabetes, Prevention, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, 6 Evaluation of treatments and therapeutic interventions, Metabolic and endocrine, 3 Good Health and Well Being, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Heart Failure, Humans, Hypertension, Male, Blood Pressure Lowering Treatment Trialists' Collaboration, anzsrc-for: 1101 Medical Biochemistry and Metabolomics, anzsrc-for: 1103 Clinical Sciences, anzsrc-for: 1117 Public Health and Health Services |
| الوصف: | Background: Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure. Methods: We conducted a one-stage individual participant-level data meta-analysis of major randomised controlled trials using the Blood Pressure Lowering Treatment Trialists' Collaboration dataset. Trials with information on type 2 diabetes status at baseline were eligible if they compared blood pressure-lowering medications versus placebo or other classes of blood pressure-lowering medications, or an intensive versus a standard blood pressure-lowering strategy, and reported at least 1000 persons-years of follow-up in each group. Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. We expressed treatment effect per 5 mm Hg reduction in systolic blood pressure on the risk of developing a major cardiovascular event as the primary outcome, defined as the first occurrence of fatal or non-fatal stroke or cerebrovascular disease, fatal or non-fatal ischaemic heart disease, or heart failure causing death or requiring hospitalisation. Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios (HRs) separately by type 2 diabetes status at baseline, with further stratification by baseline categories of systolic blood pressure (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg). To estimate absolute risk reductions, we used a Poisson regression model over the follow-up duration. The effect of each of the five major blood pressure-lowering drug classes, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, and thiazide diuretics, was estimated using a network ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | http://hdl.handle.net/1959.4/unsworks_82254Test; https://unsworks.unsw.edu.au/bitstreams/43328e56-1fbc-4dc4-8185-bea5161cb7c1/downloadTest; https://doi.org/10.1016/S2213-8587Test(22)00172-3 |
| DOI: | 10.1016/S2213-8587(22)00172-3 |
| الإتاحة: | https://doi.org/10.1016/S2213-8587Test(22)00172-3 http://hdl.handle.net/1959.4/unsworks_82254Test https://unsworks.unsw.edu.au/bitstreams/43328e56-1fbc-4dc4-8185-bea5161cb7c1/downloadTest |
| حقوق: | open access ; https://purl.org/coar/access_right/c_abf2Test ; CC BY ; https://creativecommons.org/licenses/by/4.0Test/ ; free_to_read |
| رقم الانضمام: | edsbas.256F0864 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S2213-8587(22)00172-3 |
|---|